There are a number of ADCs that have combined immune checkpoint inhibitor agents in clinical trials, some examples include T-DM1 and atezolizumab (NCT02924883) in phase Ib for the treatment of locally advanced or metastatic HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.